Apollomics Announced The Presentation Of Vebreltinib Efficacy And Safety Data From The Ongoing Multi-cohort 2 KUNPENG trial And Phase 2 SPARTA trial At The IASLC North America Conference On Lung Cancer
Author: Benzinga Newsdesk | December 04, 2023 08:03am